A Watertown biotech says is received a $112 million investment led by the investment firm that manages the assets of the Novo ...

AvenCell Therapeutics, Inc. ("AvenCell"), a leading clinical-stage cell therapy company focused on advancing both autologous and allogeneic switchable CAR-T cell therapies, today announced that it has ...

AvenCell Therapeutics has secured $112 million in series B funds as the Novo Holdings-backed biotech seeks clinical proof ...

Novo’s 2024 Sustainability Report demonstrates that Novo remains committed to sustainability as we execute our exploration ...

Discover Booster Therapeutics' novel 20S proteasome activation approach to neurodegenerative diseases as it launches with $15 ...

Berlin, Germany-based Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines ...

Novo Holdings, a leading global life sciences investor, today announced the launch of Booster Therapeutics (Booster / the Company), a biotechnology company developing a new class of proteasome ...

$1.85B Expansion in Johnston County Doubling Workforce of 700 Collaborative Success for EDPNC, NCBiotech and State/Local Officials Each Biomanufacturing Job Creates Six Total Jobs Novo Nordisk, a key ...

The Khyati Global Ventures IPO opened on October 4 and closes on October 8, priced at ₹99 per share. (https://khyatigroup.com/) The IPO subscription period for ...

In their places are projected to be Novo Nordisk's (NVO) type 2 diabetes med Ozempic (semaglutide) and Regeneron Pharmaceuticals (NASDAQ:REGN)/Sanofi's (SNY) Dupixent (dupilumab), used for ...

While online discourse would make it seem that venture has retreated to the Bay Area, with San Francisco being the most important place to build a startup, Index Ventures is looking to bulk up its ...

Sept 26 (Reuters) - German drug and development company Evotec (EVTG.DE), opens new tab has entered into a technology development partnership with Novo Nordisk (NOVOb.CO), opens new tab to support ...